A deal with Novo would enhance Hims & Hers' credibility, resolve legal disputes, and strengthen subscriber and TAM potential.

Zymeworks Inc. is rated a Buy with improved FY25 profitability, narrowed net loss by 34%, and strong liquidity with $270.6M. Read more on ZYME stock here.

Toyota’s American pick-up joins the big truck class in Australia, but can a Japanese ...

A whistleblower lawsuit against $32 billion London-based hedge fund Capula Investment Management has taken a new turn, with the firm's former US Chief Compliance Officer refiling his case in New York ...